GP Pharm Concludes Final Reports for Preclinical Studies Of Sarcodoxome®
Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP Pharm’s formulation and were performed at department of human toxicology, faculty of health, medicine and life sciences.
One of the University of Maastricht’s studies was a comparison of the cardiotoxicity of Liposomal Doxorubicin GP Pharm with free doxorubicin in the mouse using ECG Telemetry Conclusion. Based on the results of this study, it can be conclude that Liposomal doxorubicin GP Pharm is less cardiotoxic than free doxorubicin.
Another study was that of Lipocroman-6, which investigated the activity of a new antioxidant in a LPO (lipid peroxidation) in vitro system. Based on the results of this study, it can be concluded that Lipocroman-6 reduces lipid peroxidation in vitro.